Status:
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborating Sponsors:
The Cleveland Clinic
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of ...
Eligibility Criteria
Inclusion
- Subjects with osteoarthritis or rheumatoid Arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms.
Exclusion
- Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;
- Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial
- Subjects require treatment with aspirin \> 325 mg /day
- Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.
Key Trial Info
Start Date :
October 4 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2016
Estimated Enrollment :
24081 Patients enrolled
Trial Details
Trial ID
NCT00346216
Start Date
October 4 2006
End Date
April 12 2016
Last Update
March 3 2021
Active Locations (1066)
Enter a location and click search to find clinical trials sorted by distance.
1
Carol M. Johnson MD, LLC
Alabaster, Alabama, United States, 35007
2
Orthopaedics West
Bessemer, Alabama, United States, 35022
3
Central Alabama Research
Birmingham, Alabama, United States, 35209
4
Simon Williamson Clinic/Clinical Research Advantage, Inc.
Birmingham, Alabama, United States, 35211